A recent study suggests that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Published data in a major medical journal demonstrates that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these medications must be cognizant of the risk of quick weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb.
That rate of regain suggests a return to starting mass within about one and a half years.
Analyzing Treatments
The analysis, which reviewed 37 of studies involving over 9,000 of patients, contrasted the results of the injectable medications with older methods.
Researchers point out that people who shed pounds through dieting generally have a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Experts believe the way of the drugs is key to understanding the accelerated regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal might result in the system to produce less of its endogenous hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this medication leads to hunger is no longer kept in check, making overeating much more probable."
An Ongoing Disease?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
Professionals say that, considering the likelihood of weight regain, the therapy might need to be life-long.
This opinion is reinforced by drug manufacturers, who state that the results "highlight the long-term character of excess weight," akin to managing diseases like high blood pressure.
User Accounts
Users who have discontinued the jabs describe a intense return of appetite.
"It felt as if a switch that goes on and I was suddenly ravenous," described an individual.
The struggle is exacerbated if individuals have not adopted sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Figures suggest that millions of people in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is higher among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone fix and lasting health benefits likely depends on combined lifestyle changes.
